Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Germline editing is safe and improving all the time. It is key to innovating new cures to hereditary disease. The plan stops that – turns case

Li, et al. 19 Li, Yanni, et al. Key Laboratory for Major Obstetric Diseases of Guangdong Province, Center of Reproductive Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou. “Human Germline Editing: Insights to Future Clinical Treatment of Diseases.” Protein & Cell, vol. 10, no. 7, July 2019, pp. 470–475, www.ncbi.nlm.nih.gov/pmc/articles/PMC6588666/, 10.1007/s13238-018-0594-8. Accessed 30 June 2022. //DRE

Last year, the first attempt to genetically modify human embryos in the United States was reported and sparked a huge debate (Ma et al., 2017). Although the first human germline modification was only performed two years ago, the study showed that rapid advances in technology has allowed the rate of off-target effects and mosaicism to be reduced considerably (Liang et al., 2015). Recently, Vertex and CRISPR therapeutics collaborated and developed CTX001, the first CRISPR/Cas9-based therapy, targeting patients with β-thalassemia and have begun phase 1/2 clinical trials. With policies and technologies regarding genome editing both developing rapidly, explorations into the possibility of clinical gene editing for hundreds of hereditary diseases are starting to become achievable. Here, we address the progress of human embryo editing technologies so far and its promise and risks in advancing therapy for hereditary diseases. Researchers have utilized genome editing techniques to modify genetic sequences in somatic cells and germline cells to conduct basic research on gene function or disease treatment. Genetic modifications to a somatic cell are generally non-heritable as they do not contribute to gametes. However, researchers have utilized tetraploid complementation to produce genetically modified offspring from modified mouse and rat pluripotent stem cells (Eggan et al., 2002; Li et al., 2017c). On the other hand, genetic editing to an organism’s germ cells is more universally applicable and will result in the natural inheritance of the modified genome in its offspring. As current genome editing technology often introduces off-target effects such as chromosomal translocations or insertion-deletions (indels) resulting in undesired loss or gain of functions of genes, which is a safety concern when dealing with the human germline (Corrigan-Curay et al., 2015), the potential of genome editing to overcome genetic diseases is therefore held back by the risk of creating more genetic complications or even irreversibly altering the human germline through nondescript mutations. Genome editing research is rather commonplace nowadays, with CRISPR/Cas9-mediated genome modification being at the forefront since its first adaptation into eukaryotic cells (Abrahimi et al., 2015; Cao et al., 2016; Cong et al., 2013; Hsu et al., 2014; Iyer et al., 2018; Li et al., 2017b; Mali et al., 2013; Nelson et al., 2016; Noel et al., 2018; Sato et al., 2015; Savic et al., 2018; Schwank et al., 2013; Shalem et al., 2014; Shen et al., 2014; Slaymaker et al., 2016; Wu et al., 2013). The diverse amounts of ex vivo and in vivo experiments conducted have resulted in the genome editing protocol to be significantly improved in the last 5 years. Today, nuclease delivery into cells for genome editing can be either in the form of RNA or protein for enhanced kinetics of action and nuclease turnover, while also preventing integration of exogenous DNA into the host genome (Abou-El-Enein et al., 2017). Efficient and precise gene correction for mutations takes advantage of the cell cycle, relying on the homology-directed repair (HDR) pathway which functions in the late S–G2 phase (Chapman et al., 2012; Heyer et al., 2010). In the recent year, germline editing has become a hot topic in scientific research. CRISPR/Cas9 microinjections into mouse zygotes have been shown to correct disease associated mutations, producing healthy adult animals (Wang et al., 2013; Wu et al., 2013). Likewise, CRISPR/Cas9 and TALEN have both effectively generated germline mutations in fertilized monkey embryos (Liu et al., 2014; Niu et al., 2014). With numerous successes in both somatic and germline genome editing in animal models, researchers have started to consider the possibility of translating the protocol to edit the human genome for clinical purposes (Cornu et al., 2017). For the first time, US National Academy of Sciences and National Academy of Medicine relaxed stance on modification of germline in February 2015 followed by the first reports of gene editing in human embryos. Tripronuclear (3PN) zygotes which were discarded from clinics were used by a group in China to attempt CRISPR/Cas9-mediated gene editing of human endogenous β-globin gene (HBB). They found that the efficiency of single-stranded oligonucleotides (ssODNs) mediated HDR was low and successfully edited embryos exhibited mosaicism i.e., only a portion of the cells were successfully modified, while the remaining cells remained as wild type (Liang et al., 2015). In addition, whole-exome sequencing revealed off-target mutations in these 3PN embryos. Moreover, the researchers identified that although the endogenous delta-globin gene (HBD), a HBB homolog, also functions as a template to compete with ssODNs for HDR repair, majority of the double-stranded breaks (DSBs) caused by Cas9 were repaired through the unideal error-prone non-homologous end joining (NHEJ) pathway.

Sign in to recut, update, or save this card.